Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRSTx: CXA-10 in Primary FSGS
NCT03422510Phase 2Completed
- Sponsor
- Complexa Therapeutics
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 10-nitro-oleic acid in focal segmental glomerulosclerosis (FSGS), sponsored by Complexa Therapeutics. Started Apr 2018; status: completed.
02
Drugs
10-nitro-oleic acid
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03422510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422510.